Patents Assigned to Black Diamond Therapeutics, Inc.
  • QUINOXALINE DERIVATIVES AND USES THEREOF
    Publication number: 20240368181
    Abstract: The present disclosure relates compounds of Formula (I?): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds, e.g., in the treatment of cancer.
    Type: Application
    Filed: February 4, 2022
    Publication date: November 7, 2024
    Applicant: Black Diamond Therapeutics, Inc.
    Inventors: Matthew C. LUCAS, Fernando PADILLA
  • 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES
    Publication number: 20240317752
    Abstract: The present disclosure relates compounds of Formula (I?): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds, e.g., in the treatment of cancer.
    Type: Application
    Filed: February 18, 2022
    Publication date: September 26, 2024
    Applicant: Black Diamond Therapeutics, Inc.
    Inventors: Pui Yee NG, Ivan JEWETT, Matthew C. LUCAS, Fernando PADILLA, Istvan J. ENYEDY
  • TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE
    Publication number: 20220363666
    Abstract: The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).
    Type: Application
    Filed: March 12, 2021
    Publication date: November 17, 2022
    Applicant: Black Diamond Therapeutics, Inc.
    Inventors: Alexander FLOHR, Alexander MAYWEG, George TRAINOR, David M. EPSTEIN, Matthew O'CONNOR, Elizabeth BUCK, Luca ARISTA
  • Tyrosine kinase inhibitor compositions, methods of making and methods of use
    Patent number: 11034672
    Abstract: The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: June 15, 2021
    Assignee: Black Diamond Therapeutics, Inc.
    Inventors: Alexander Flohr, Alexander Mayweg, George Trainor, David M. Epstein, Matthew O'Connor, Elizabeth Buck, Luca Arista